DE60030698D1 - Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln - Google Patents

Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln

Info

Publication number
DE60030698D1
DE60030698D1 DE60030698T DE60030698T DE60030698D1 DE 60030698 D1 DE60030698 D1 DE 60030698D1 DE 60030698 T DE60030698 T DE 60030698T DE 60030698 T DE60030698 T DE 60030698T DE 60030698 D1 DE60030698 D1 DE 60030698D1
Authority
DE
Germany
Prior art keywords
virgin
vaccine
disassembled
producing
human papilloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030698T
Other languages
English (en)
Other versions
DE60030698T2 (de
Inventor
B Volkin
Henryk Mach
Li Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60030698(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE60030698D1 publication Critical patent/DE60030698D1/de
Application granted granted Critical
Publication of DE60030698T2 publication Critical patent/DE60030698T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60030698T 1999-03-26 2000-03-22 Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln Expired - Lifetime DE60030698T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US524624 1990-05-17
US12652899P 1999-03-26 1999-03-26
US126528P 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (2)

Publication Number Publication Date
DE60030698D1 true DE60030698D1 (de) 2006-10-26
DE60030698T2 DE60030698T2 (de) 2007-07-19

Family

ID=26824774

Family Applications (4)

Application Number Title Priority Date Filing Date
DE200712000034 Pending DE122007000034I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln
DE200712000033 Pending DE122007000033I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln
DE60030698T Expired - Lifetime DE60030698T2 (de) 1999-03-26 2000-03-22 Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln
DE200712000032 Pending DE122007000032I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und Reassembliertenn Virusaehnlichen Partikeln

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE200712000034 Pending DE122007000034I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln
DE200712000033 Pending DE122007000033I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE200712000032 Pending DE122007000032I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und Reassembliertenn Virusaehnlichen Partikeln

Country Status (19)

Country Link
US (2) US6245568B1 (de)
EP (1) EP1165126B1 (de)
JP (1) JP4594534B2 (de)
KR (1) KR20020013516A (de)
AR (1) AR023166A1 (de)
AT (1) ATE339222T1 (de)
AU (1) AU778937B2 (de)
CA (1) CA2368391C (de)
CY (4) CY1105779T1 (de)
DE (4) DE122007000034I1 (de)
DK (1) DK1165126T3 (de)
ES (1) ES2270822T3 (de)
FR (1) FR07C0026I2 (de)
LT (1) LTC1165126I2 (de)
LU (3) LU91326I2 (de)
NL (3) NL300268I1 (de)
PT (1) PT1165126E (de)
SI (1) SI1165126T1 (de)
WO (1) WO2000057906A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
EP1250593B1 (de) * 1999-12-09 2009-03-25 Medimmune, Inc. In-vitro-methode zur zerlegung und zum wiederzusammenfügen von papillomavirusartigen partikeln
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
MY132859A (en) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
DK1572233T3 (da) 2002-12-20 2011-06-27 Glaxosmithkline Biolog Sa Anvendelse af HPV16 og HPV18 som vaccine mod et eller flere onkogene HPV-vira af typerne 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1785433A4 (de) * 2004-07-01 2008-10-01 Tokyo Inst Tech Viruspartikelähnliches konstrukt und verfahren zu dessen bildung unter physiologischen bedingungen
EP1841474A2 (de) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Verfahren zur diafiltrierung
JP2009501520A (ja) * 2005-07-14 2009-01-22 メイヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パラミクソウイルス科ウイルス調製物
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
WO2007027076A1 (es) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
EP2258380B1 (de) * 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nukleinsäure zur erhöhung der wärmeresistenz von lactoferrin
DK2473596T3 (en) * 2009-09-03 2018-01-22 Becton Dickinson Co METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS
PL2608805T3 (pl) 2010-08-23 2017-12-29 Wyeth Llc Trwałe preparaty antygenów rLP2086 Neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人***状瘤病毒的接种方法
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (de) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
EP3577130A2 (de) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
NZ500028A (en) 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
PT1165126E (pt) 2006-12-29
NL300268I1 (nl) 2007-05-01
CA2368391C (en) 2011-06-07
LU91328I9 (de) 2019-03-01
EP1165126A1 (de) 2002-01-02
CY2007010I1 (el) 2009-11-04
NL300269I2 (nl) 2008-07-01
CA2368391A1 (en) 2000-10-05
LTPA2007002I1 (lt) 2020-03-25
AU3909300A (en) 2000-10-16
LU91327I2 (fr) 2007-05-14
LTC1165126I2 (lt) 2020-04-27
US20010021385A1 (en) 2001-09-13
FR07C0026I1 (de) 2007-04-27
SI1165126T1 (sl) 2006-12-31
LU91327I9 (de) 2019-03-01
DE122007000032I1 (de) 2007-08-09
US6245568B1 (en) 2001-06-12
DE122007000033I1 (de) 2007-08-09
LU91326I2 (fr) 2007-05-14
CY2007010I2 (el) 2009-11-04
NL300269I1 (nl) 2007-05-01
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
LU91326I9 (de) 2018-12-31
JP4594534B2 (ja) 2010-12-08
FR07C0026I2 (fr) 2012-08-03
JP2002540167A (ja) 2002-11-26
LU91328I2 (fr) 2007-05-14
EP1165126B1 (de) 2006-09-13
AU778937B2 (en) 2004-12-23
AR023166A1 (es) 2002-09-04
CY2007008I2 (el) 2009-11-04
NL300270I1 (nl) 2007-05-01
WO2000057906A1 (en) 2000-10-05
ES2270822T3 (es) 2007-04-16
CY2007008I1 (el) 2009-11-04
CY2007009I2 (el) 2010-07-28
DE122007000034I1 (de) 2007-08-09
DK1165126T3 (da) 2007-01-08
CY2007009I1 (el) 2010-07-28
KR20020013516A (ko) 2002-02-20
DE60030698T2 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
DE60030698D1 (de) Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln
DE60005793D1 (de) Verfahren zur herstellung eines schleifgegenstandes und damit hergestellte schleifgegenstände
DE60028870D1 (de) Verfahren und Vorrichtung zur Herstellung eines zweiteiligen Kolbens
DE60019052D1 (de) Verfahren und Vorrichtung zur Herstellung eines geformten Geräts
DE60032248D1 (de) Verfahren zur herstellung eines rohrstücks in einem strukturbauteil und matrize hierfür
DE60021055D1 (de) Gefaltetes filterelement und verfahren zur herstellung eines gefalteten filterelements
DE60035360D1 (de) Vorrichtung und verfahren zur herstellung eines mechanischen befestigungselements
DE50001218D1 (de) Vorrichtung und verfahren zur generativen herstellung eines dreidimensionalen objektes
DE69836353D1 (de) Verfahren zur Herstellung eines Laminats und daraus hergestellte Gegenstände
DE60204022D1 (de) Verfahren zur herstellung eines poly(arylenether)s und danach hergestellter poly(arylenether)
DE59503282D1 (de) Verfahren zur herstellung eines wasserabsorbierenden flächengebildes und verwendung
DE50006246D1 (de) Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenwaren
DE60111165D1 (de) Verfahren zur Herstellung eines Glasmatrixverbundwerkstoffes und Glasmatrixverbundwerkstoff
DE10084693T1 (de) System und Verfahren zur Herstellung eines Preßholzproduktes
DE60120346D1 (de) Verfahren und Vorrichtung zur Herstellung eines gefriergetrockneten Produktes
DE50001155D1 (de) Verfahren zur Herstellung eines Stutzens
DE60000465D1 (de) Verfahren und Vorrichtung zur Herstellung eines Verbundmaterials
DE50007346D1 (de) Lautsprecher mit einem frontseitig aufgesetzten Dichtelement und Verfahren zur Herstellung eines solchen Lautsprechers
DE60135715D1 (de) Signalleuchte mit einem vereinfachten Aufbau und Verfahren zur Herstellung eines solchen Aufbaus
DE69513360T2 (de) Verfahren zur Herstellung eines hohlen Strukturelements und hohles Strukturelement
DE60018562D1 (de) Verfahren und einrichtung zur herstellung eines pfahls in den boden
DE59702129D1 (de) Verfahren zur Herstellung eines Zierteiles und Zierteil
DE60139452D1 (de) Verfahren zur Herstellung eines Blutsammelbehälters und eines Zusatzes
DE50115727D1 (de) Piezoaktor und verfahren zur herstellung eines piezoaktors
DE50001906D1 (de) Verfahren zur herstellung eines gesinterten wabenkörpers

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: IMPFSTOFF, DER L1-PROTEINE AUS DEN TYPEN 6, 11, 16 UND 18 DES HUMANEN PAPILLOMAVIRUS ENTHAELT, JEWEILS IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/06/357/001-017, 20060920

Spc suppl protection certif: 12 2007 000 032

Filing date: 20070319

Free format text: PRODUCT NAME: IMPFSTOFF, DER L1-PROTEINE AUS DEN TYPEN 6, 11, 16 UND 18 DES HUMANEN PAPILLOMAVIRUS ENTHAELT, JEWEILS IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/06/358/001-017, 20060920

Spc suppl protection certif: 12 2007 000 033

Filing date: 20070319

Free format text: PRODUCT NAME: IMPFSTOFF, DER L1-PROTEINE AUS DEN TYPEN 6, 11, 16 UND 18 DES HUMANEN PAPILLOMAVIRUS ENTHAELT, JEWEILS IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 034

Filing date: 20070319

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1165126

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1165126

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213